{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T12:45:44Z","timestamp":1785156344259,"version":"3.55.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,3,2]],"date-time":"2023-03-02T00:00:00Z","timestamp":1677715200000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004721","name":"The University of Tokyo","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004721","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2023,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>Patients with pancreatic cancer often have cancer cachexia at diagnosis. Recent studies suggested that loss of skeletal muscle mass was related to cancer cachexia, which hindered continuance of chemotherapy and could be one of prognostic factors in pancreatic cancer, however the association remains unclear in patients receiving gemcitabine and nab-paclitaxel (GnP).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We retrospectively studied 138 patients with unresectable pancreatic cancer receiving first-line GnP at the University of Tokyo from January 2015 to September 2020. We calculated body composition in CT images before chemotherapy and at initial evaluation, and evaluated the association of both body composition before chemotherapy and its changes at initial evaluation.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Compared by skeletal muscle mass index (SMI) change rate between pre-chemotherapy and initial evaluation, there were statistically significantly differences in the median OS: 16.3\u00a0months (95%CI 12.3\u201322.7) and 10.3\u00a0months (95%CI 8.3\u201318.1) between SMI change rate\u2009\u2265\u2009-3.5% and\u2009&lt;\u2009-3.5% groups (<jats:italic>P<\/jats:italic>\u2009=\u20090.01). By multivariate analysis for OS, CA19-9 (HR 3.34, 95%CI 2.00\u20135.57, <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.01), PLR (HR 1.68, 95%CI 1.01\u20132.78, <jats:italic>P<\/jats:italic>\u2009=\u20090.04), mGPS (HR 2.32, 95%CI 1.47\u20133.65, <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.01) and relative dose intensity (HR 2.21, 95%CI 1.42\u20133.46, <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.01) were significantly poor prognostic factors. SMI change rate (HR 1.47, 95%CI 0.95\u20132.28, <jats:italic>P<\/jats:italic>\u2009=\u20090.08) showed a trend to poor prognosis. Sarcopenia before chemotherapy was not significantly associated with PFS or OS.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Early skeletal muscle mass decline was associated with poor OS. Further investigation is warranted whether the maintenance of skeletal muscle mass by nutritional support would improve prognosis.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00520-023-07659-w","type":"journal-article","created":{"date-parts":[[2023,3,2]],"date-time":"2023-03-02T07:02:50Z","timestamp":1677740570000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Early skeletal muscle mass decline is a prognostic factor in patients receiving gemcitabine plus nab-paclitaxel for unresectable pancreatic cancer: a retrospective observational study"],"prefix":"10.1007","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9625-4616","authenticated-orcid":false,"given":"Yukari","family":"Suzuki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kei","family":"Saito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yousuke","family":"Nakai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroki","family":"Oyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sachiko","family":"Kanai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsunori","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuya","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryunosuke","family":"Hakuta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazunaga","family":"Ishigaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomotaka","family":"Saito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsuyoshi","family":"Hamada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naminatsu","family":"Takahara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryosuke","family":"Tateishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsuhiro","family":"Fujishiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,3,2]]},"reference":[{"issue":"1","key":"7659_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21654","volume":"71","author":"RL Siegel","year":"2021","unstructured":"Siegel RL, Miller KD, Fuchs HE, Jemal A (2021) Cancer Statistics, 2021. CA Cancer J Clin 71(1):7\u201333. https:\/\/doi.org\/10.3322\/caac.21654","journal-title":"CA Cancer J Clin"},{"issue":"10242","key":"7659_CR2","doi-asserted-by":"publisher","first-page":"2008","DOI":"10.1016\/s0140-6736(20)30974-0","volume":"395","author":"JD Mizrahi","year":"2020","unstructured":"Mizrahi JD, Surana R, Valle JW, Shroff RT (2020) Pancreatic cancer. Lancet 395(10242):2008\u20132020. https:\/\/doi.org\/10.1016\/s0140-6736(20)30974-0","journal-title":"Lancet"},{"issue":"1","key":"7659_CR3","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21590","volume":"70","author":"RL Siegel","year":"2020","unstructured":"Siegel RL, Miller KD, Jemal A (2020) Cancer statistics, 2020. CA Cancer J Clin 70(1):7\u201330. https:\/\/doi.org\/10.3322\/caac.21590","journal-title":"CA Cancer J Clin"},{"issue":"18","key":"7659_CR4","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1056\/NEJMoa1304369","volume":"369","author":"DD Von Hoff","year":"2013","unstructured":"Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M et al (2013) Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 369(18):1691\u20131703. https:\/\/doi.org\/10.1056\/NEJMoa1304369","journal-title":"N Engl J Med"},{"issue":"19","key":"7659_CR5","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","volume":"364","author":"T Conroy","year":"2011","unstructured":"Conroy T, Desseigne F, Ychou M, Bouch\u00e9 O, Guimbaud R, B\u00e9couarn Y et al (2011) FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 364(19):1817\u20131825. https:\/\/doi.org\/10.1056\/NEJMoa1011923","journal-title":"N Engl J Med"},{"issue":"11","key":"7659_CR6","doi-asserted-by":"publisher","first-page":"5271","DOI":"10.1007\/s00520-020-05346-8","volume":"28","author":"S Mitsunaga","year":"2020","unstructured":"Mitsunaga S, Kasamatsu E, Machii K (2020) Incidence and frequency of cancer cachexia during chemotherapy for advanced pancreatic ductal adenocarcinoma. Support Care Cancer 28(11):5271\u20135279. https:\/\/doi.org\/10.1007\/s00520-020-05346-8","journal-title":"Support Care Cancer"},{"issue":"7","key":"7659_CR7","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1007\/s10147-021-01912-0","volume":"26","author":"T Takeda","year":"2021","unstructured":"Takeda T, Sasaki T, Suzumori C, Mie T, Furukawa T, Yamada Y et al (2021) The impact of cachexia and sarcopenia in elderly pancreatic cancer patients receiving palliative chemotherapy. Int J Clin Oncol 26(7):1293\u20131303. https:\/\/doi.org\/10.1007\/s10147-021-01912-0","journal-title":"Int J Clin Oncol"},{"issue":"5","key":"7659_CR8","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/s1470-2045(10)70218-7","volume":"12","author":"K Fearon","year":"2011","unstructured":"Fearon K, Strasser F, Anker SD, Bosaeus I, Bruera E, Fainsinger RL et al (2011) Definition and classification of cancer cachexia: an international consensus. Lancet Oncol 12(5):489\u2013495. https:\/\/doi.org\/10.1016\/s1470-2045(10)70218-7","journal-title":"Lancet Oncol"},{"issue":"12","key":"7659_CR9","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1200\/jco.2012.45.2722","volume":"31","author":"L Martin","year":"2013","unstructured":"Martin L, Birdsell L, Macdonald N, Reiman T, Clandinin MT, McCargar LJ et al (2013) Cancer cachexia in the age of obesity: skeletal muscle depletion is a powerful prognostic factor, independent of body mass index. J Clin Oncol 31(12):1539\u20131547. https:\/\/doi.org\/10.1200\/jco.2012.45.2722","journal-title":"J Clin Oncol"},{"issue":"11","key":"7659_CR10","doi-asserted-by":"publisher","first-page":"8662","DOI":"10.1007\/s00330-021-07899-6","volume":"31","author":"E Salinas-Miranda","year":"2021","unstructured":"Salinas-Miranda E, Deniffel D, Dong X, Healy GM, Khalvati F, O\u2019Kane GM et al (2021) Prognostic value of early changes in CT-measured body composition in patients receiving chemotherapy for unresectable pancreatic cancer. Eur Radiol 31(11):8662\u20138670. https:\/\/doi.org\/10.1007\/s00330-021-07899-6","journal-title":"Eur Radiol"},{"issue":"13","key":"7659_CR11","doi-asserted-by":"publisher","first-page":"4291","DOI":"10.1002\/cam4.3964","volume":"10","author":"O Nakano","year":"2021","unstructured":"Nakano O, Kawai H, Kobayashi T, Kohisa J, Ikarashi S, Hayashi K et al (2021) Rapid decline in visceral adipose tissue over 1 month is associated with poor prognosis in patients with unresectable pancreatic cancer. Cancer Med 10(13):4291\u20134301. https:\/\/doi.org\/10.1002\/cam4.3964","journal-title":"Cancer Med"},{"key":"7659_CR12","doi-asserted-by":"publisher","unstructured":"Choi Y, Oh DY, Kim TY, Lee KH, Han SW, Im SA et al (2015) Skeletal Muscle Depletion Predicts the Prognosis of Patients with Advanced Pancreatic Cancer Undergoing Palliative Chemotherapy, Independent of Body Mass Index. PLoS One 10(10):e0139749. https:\/\/doi.org\/10.1371\/journal.pone.0139749","DOI":"10.1371\/journal.pone.0139749"},{"issue":"6","key":"7659_CR13","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1016\/j.pan.2019.07.039","volume":"19","author":"OM Griffin","year":"2019","unstructured":"Griffin OM, Duggan SN, Ryan R, McDermott R, Geoghegan J, Conlon KC (2019) Characterising the impact of body composition change during neoadjuvant chemotherapy for pancreatic cancer. Pancreatology 19(6):850\u2013857. https:\/\/doi.org\/10.1016\/j.pan.2019.07.039","journal-title":"Pancreatology"},{"issue":"1","key":"7659_CR14","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.pan.2018.11.001","volume":"19","author":"Y Kurita","year":"2019","unstructured":"Kurita Y, Kobayashi N, Tokuhisa M, Goto A, Kubota K, Endo I et al (2019) Sarcopenia is a reliable prognostic factor in patients with advanced pancreatic cancer receiving FOLFIRINOX chemotherapy. Pancreatology 19(1):127\u2013135. https:\/\/doi.org\/10.1016\/j.pan.2018.11.001","journal-title":"Pancreatology"},{"issue":"10","key":"7659_CR15","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1017\/S0007114520003463","volume":"125","author":"S Uemura","year":"2021","unstructured":"Uemura S, Iwashita T, Ichikawa H, Iwasa Y, Mita N, Shiraki M et al (2021) The impact of sarcopenia and decrease in skeletal muscle mass in patients with advanced pancreatic cancer during FOLFIRINOX therapy. Br J Nutr 125(10):1140\u20131147. https:\/\/doi.org\/10.1017\/S0007114520003463","journal-title":"Br J Nutr"},{"issue":"2","key":"7659_CR16","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1097\/mpa.0000000000001985","volume":"51","author":"H Asama","year":"2022","unstructured":"Asama H, Ueno M, Kobayashi S, Fukushima T, Kawano K, Sano Y et al (2022) Sarcopenia: prognostic value for unresectable pancreatic ductal adenocarcinoma patients treated with gemcitabine plus Nab-Paclitaxel. Pancreas 51(2):148\u2013152. https:\/\/doi.org\/10.1097\/mpa.0000000000001985","journal-title":"Pancreas"},{"issue":"3","key":"7659_CR17","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1007\/s00280-016-2972-3","volume":"77","author":"H Ueno","year":"2016","unstructured":"Ueno H, Ikeda M, Ueno M, Mizuno N, Ioka T, Omuro Y et al (2016) Phase I\/II study of nab-paclitaxel plus gemcitabine for chemotherapy-naive Japanese patients with metastatic pancreatic cancer. Cancer Chemother Pharmacol 77(3):595\u2013603. https:\/\/doi.org\/10.1007\/s00280-016-2972-3","journal-title":"Cancer Chemother Pharmacol"},{"issue":"6","key":"7659_CR18","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1093\/annonc\/mdv112","volume":"26","author":"C Cremolini","year":"2015","unstructured":"Cremolini C, Loupakis F, Antoniotti C, Lonardi S, Masi G, Salvatore L et al (2015) Early tumor shrinkage and depth of response predict long-term outcome in metastatic colorectal cancer patients treated with first-line chemotherapy plus bevacizumab: results from phase III TRIBE trial by the Gruppo Oncologico del Nord Ovest. Ann Oncol 26(6):1188\u20131194. https:\/\/doi.org\/10.1093\/annonc\/mdv112","journal-title":"Ann Oncol"},{"issue":"14","key":"7659_CR19","doi-asserted-by":"publisher","first-page":"1927","DOI":"10.1016\/j.ejca.2015.06.116","volume":"51","author":"V Heinemann","year":"2015","unstructured":"Heinemann V, Stintzing S, Modest DP, Giessen-Jung C, Michl M, Mansmann UR (2015) Early tumour shrinkage (ETS) and depth of response (DpR) in the treatment of patients with metastatic colorectal cancer (mCRC). Eur J Cancer 51(14):1927\u20131936. https:\/\/doi.org\/10.1016\/j.ejca.2015.06.116","journal-title":"Eur J Cancer"},{"key":"7659_CR20","doi-asserted-by":"publisher","unstructured":"Vivaldi C, Fornaro L, Cappelli C, Pecora I, Catanese S, Salani F et al (2019) Early Tumor Shrinkage and Depth of Response Evaluation in Metastatic Pancreatic Cancer Treated with First Line Chemotherapy: An Observational Retrospective Cohort Study. Cancers (Basel) 11(7). https:\/\/doi.org\/10.3390\/cancers11070939","DOI":"10.3390\/cancers11070939"},{"issue":"1","key":"7659_CR21","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.jhep.2015.02.031","volume":"63","author":"N Fujiwara","year":"2015","unstructured":"Fujiwara N, Nakagawa H, Kudo Y, Tateishi R, Taguri M, Watadani T et al (2015) Sarcopenia, intramuscular fat deposition, and visceral adiposity independently predict the outcomes of hepatocellular carcinoma. J Hepatol 63(1):131\u2013140. https:\/\/doi.org\/10.1016\/j.jhep.2015.02.031","journal-title":"J Hepatol"},{"key":"7659_CR22","doi-asserted-by":"publisher","unstructured":"Mitsiopoulos N, Baumgartner RN, Heymsfield SB, Lyons W, Gallagher D, Ross R (1998) Cadaver validation of skeletal muscle measurement by magnetic resonance imaging and computerized tomography. J Appl Physiol (1985) 85(1):115\u201322. https:\/\/doi.org\/10.1152\/jappl.1998.85.1.115","DOI":"10.1152\/jappl.1998.85.1.115"},{"issue":"10","key":"7659_CR23","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1111\/hepr.12774","volume":"46","author":"H Nishikawa","year":"2016","unstructured":"Nishikawa H, Shiraki M, Hiramatsu A, Moriya K, Hino K, Nishiguchi S (2016) Japan Society of Hepatology guidelines for sarcopenia in liver disease (1st edition): Recommendation from the working group for creation of sarcopenia assessment criteria. Hepatol Res 46(10):951\u2013963. https:\/\/doi.org\/10.1111\/hepr.12774","journal-title":"Hepatol Res"},{"issue":"2","key":"7659_CR24","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.jamda.2013.11.025","volume":"15","author":"LK Chen","year":"2014","unstructured":"Chen LK, Liu LK, Woo J, Assantachai P, Auyeung TW, Bahyah KS et al (2014) Sarcopenia in Asia: consensus report of the Asian Working Group for Sarcopenia. J Am Med Dir Assoc 15(2):95\u2013101. https:\/\/doi.org\/10.1016\/j.jamda.2013.11.025","journal-title":"J Am Med Dir Assoc"},{"key":"7659_CR25","doi-asserted-by":"publisher","unstructured":"Naumann P, Eberlein J, Farnia B, Hackert T, Debus J, Combs SE (2019) Continued Weight Loss and Sarcopenia Predict Poor Outcomes in Locally Advanced Pancreatic Cancer Treated with Chemoradiation. Cancers (Basel) 11(5). https:\/\/doi.org\/10.3390\/cancers11050709","DOI":"10.3390\/cancers11050709"},{"issue":"2","key":"7659_CR26","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1002\/jcsm.12368","volume":"10","author":"D Basile","year":"2019","unstructured":"Basile D, Parnofiello A, Vitale MG, Cortiula F, Gerratana L, Fanotto V et al (2019) The IMPACT study: early loss of skeletal muscle mass in advanced pancreatic cancer patients. J Cachexia Sarcopenia Muscle 10(2):368\u2013377. https:\/\/doi.org\/10.1002\/jcsm.12368","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"7659_CR27","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.ejca.2017.02.010","volume":"76","author":"JC Lee","year":"2017","unstructured":"Lee JC, Kim JW, Ahn S, Kim HW, Lee J, Kim YH et al (2017) Optimal dose reduction of FOLFIRINOX for preserving tumour response in advanced pancreatic cancer: Using cumulative relative dose intensity. Eur J Cancer 76:125\u2013133. https:\/\/doi.org\/10.1016\/j.ejca.2017.02.010","journal-title":"Eur J Cancer"},{"key":"7659_CR28","doi-asserted-by":"publisher","first-page":"175883592110298","DOI":"10.1177\/17588359211029825","volume":"13","author":"A Vary","year":"2021","unstructured":"Vary A, Lebellec L, Di Fiore F, Penel N, Cheymol C, Rad E et al (2021) FOLFIRINOX relative dose intensity and disease control in advanced pancreatic adenocarcinoma. Ther Adv Med Oncol 13:17588359211029824. https:\/\/doi.org\/10.1177\/17588359211029825","journal-title":"Ther Adv Med Oncol"},{"issue":"23","key":"7659_CR29","doi-asserted-by":"publisher","first-page":"4294","DOI":"10.1002\/cncr.32406","volume":"125","author":"S Hamauchi","year":"2019","unstructured":"Hamauchi S, Furuse J, Takano T, Munemoto Y, Furuya K, Baba H et al (2019) A multicenter, open-label, single-arm study of anamorelin (ONO-7643) in advanced gastrointestinal cancer patients with cancer cachexia. Cancer 125(23):4294\u20134302. https:\/\/doi.org\/10.1002\/cncr.32406","journal-title":"Cancer"},{"issue":"7","key":"7659_CR30","doi-asserted-by":"publisher","first-page":"4792","DOI":"10.1016\/j.clnu.2021.06.011","volume":"40","author":"Y Hasegawa","year":"2021","unstructured":"Hasegawa Y, Ijichi H, Saito K, Ishigaki K, Takami M, Sekine R et al (2021) Protein intake after the initiation of chemotherapy is an independent prognostic factor for overall survival in patients with unresectable pancreatic cancer: A prospective cohort study. Clin Nutr 40(7):4792\u20134798. https:\/\/doi.org\/10.1016\/j.clnu.2021.06.011","journal-title":"Clin Nutr"},{"key":"7659_CR31","doi-asserted-by":"publisher","unstructured":"Kim SH, Lee SM, Jeung HC, Lee IJ, Park JS, Song M et al (2019) The Effect of Nutrition Intervention with Oral Nutritional Supplements on Pancreatic and Bile Duct Cancer Patients Undergoing Chemotherapy. Nutrients 11(5). https:\/\/doi.org\/10.3390\/nu11051145","DOI":"10.3390\/nu11051145"},{"issue":"3","key":"7659_CR32","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1097\/mpa.0000000000000767","volume":"46","author":"T Saito","year":"2017","unstructured":"Saito T, Hirano K, Isayama H, Nakai Y, Saito K, Umefune G et al (2017) The Role of Pancreatic Enzyme Replacement Therapy in Unresectable Pancreatic Cancer: A Prospective Cohort Study. Pancreas 46(3):341\u2013346. https:\/\/doi.org\/10.1097\/mpa.0000000000000767","journal-title":"Pancreas"},{"issue":"7","key":"7659_CR33","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1097\/mpa.0000000000001079","volume":"47","author":"T Saito","year":"2018","unstructured":"Saito T, Nakai Y, Isayama H, Hirano K, Ishigaki K, Hakuta R et al (2018) A Multicenter Open-Label Randomized Controlled Trial of Pancreatic Enzyme Replacement Therapy in Unresectable Pancreatic Cancer. Pancreas 47(7):800\u2013806. https:\/\/doi.org\/10.1097\/mpa.0000000000001079","journal-title":"Pancreas"},{"issue":"3","key":"7659_CR34","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1016\/j.critrevonc.2010.05.007","volume":"78","author":"Y Nakai","year":"2011","unstructured":"Nakai Y, Isayama H, Sasaki T, Sasahira N, Tsujino T, Kogure H et al (2011) Comorbidity, not age, is prognostic in patients with advanced pancreatic cancer receiving gemcitabine-based chemotherapy. Crit Rev Oncol Hematol 78(3):252\u2013259. https:\/\/doi.org\/10.1016\/j.critrevonc.2010.05.007","journal-title":"Crit Rev Oncol Hematol"},{"issue":"24","key":"7659_CR35","doi-asserted-by":"publisher","first-page":"2595","DOI":"10.1200\/jco.2013.54.8347","volume":"32","author":"H Wildiers","year":"2014","unstructured":"Wildiers H, Heeren P, Puts M, Topinkova E, Janssen-Heijnen ML, Extermann M et al (2014) International Society of Geriatric Oncology consensus on geriatric assessment in older patients with cancer. J Clin Oncol 32(24):2595\u20132603. https:\/\/doi.org\/10.1200\/jco.2013.54.8347","journal-title":"J Clin Oncol"},{"issue":"5","key":"7659_CR36","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1016\/j.jgo.2018.03.014","volume":"9","author":"ME Hamaker","year":"2018","unstructured":"Hamaker ME, Te Molder M, Thielen N, van Munster BC, Schiphorst AH, van Huis LH (2018) The effect of a geriatric evaluation on treatment decisions and outcome for older cancer patients - A systematic review. J Geriatr Oncol 9(5):430\u2013440. https:\/\/doi.org\/10.1016\/j.jgo.2018.03.014","journal-title":"J Geriatr Oncol"},{"issue":"3","key":"7659_CR37","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1016\/j.jamda.2019.12.012","volume":"21","author":"LK Chen","year":"2020","unstructured":"Chen LK, Woo J, Assantachai P, Auyeung TW, Chou MY, Iijima K et al (2020) Asian Working Group for Sarcopenia: 2019 Consensus Update on Sarcopenia Diagnosis and Treatment. J Am Med Dir Assoc 21(3):300\u20137.e2. https:\/\/doi.org\/10.1016\/j.jamda.2019.12.012","journal-title":"J Am Med Dir Assoc"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-023-07659-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00520-023-07659-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-023-07659-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,13]],"date-time":"2023-03-13T06:09:39Z","timestamp":1678687779000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00520-023-07659-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":37,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["7659"],"URL":"https:\/\/doi.org\/10.1007\/s00520-023-07659-w","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"24 June 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 February 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 March 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study was performed in line with the principals of the declaration of Helsinki. The study was approved by the ethics committee of the University of Tokyo Hospital.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Consent to publish was received from all individual participants included in the study.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Youske Nakai has received research grants by Taiho Pharmaceutical. No funding agency had input into the design and conduct of this study.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"197"}}